A plain language guide to common prostate cancer medications, the disease settings public sources associate with them, and why medication history can raise timing questions without proving a delayed diagnosis. This is not medical advice or a treatment guide.
This guide explains common medications used in prostate cancer care and the disease settings public sources associate with them. It is educational only. It is not a diagnosis tool, not medical advice, not a treatment guide, and not a statement that any medication means a person has a legal case.
The U.S. Food and Drug Administration (FDA) is the federal agency that approves drug labels. The National Cancer Institute (NCI) publishes cancer treatment summaries. The Surveillance, Epidemiology, and End Results Program (SEER) is an NCI cancer registry program that reports population statistics. Prostate-specific antigen (PSA) is a blood test marker that can be elevated for several reasons, not only cancer.
Terms used below include androgen deprivation therapy (ADT), treatment that lowers androgen hormone activity, luteinizing hormone-releasing hormone (LHRH) agonists and gonadotropin-releasing hormone (GnRH) antagonists, medicines that suppress testosterone signaling, prostate-specific membrane antigen (PSMA), a marker used for some imaging and targeted therapies, cytochrome P450 17A1 (CYP17), an enzyme involved in androgen production, poly ADP-ribose polymerase (PARP) inhibitors, drugs aimed at DNA repair pathways, homologous recombination repair (HRR), a DNA repair pathway, and BRCA1 or BRCA2, genes used in some biomarker-selected labels.
Medication history can sometimes help a patient or family ask better questions. Some drugs are mainly used for metastatic, castration-resistant, bone-metastatic, PSMA-positive, or biomarker-selected disease. Other drugs are used in early, localized, locally advanced, recurrent, bone-health, or non-prostate settings. The records, not the medication name alone, determine what happened.
Hormone therapy and androgen blocking drugs
These medicines lower testosterone or block androgen signaling. They can be used across several prostate cancer settings, so context matters.
| Medication (brand) | Drug class | Public source disease setting |
|---|---|---|
| leuprolide (Lupron, Lupron Depot, Eligard) | ADT and LHRH agonist | Advanced prostate cancer and sometimes localized or locally advanced cancer when given with radiation |
| goserelin (Zoladex) | ADT and LHRH agonist | Advanced prostate cancer and sometimes radiation-adjunct treatment, with non-prostate uses also possible |
| triptorelin (Trelstar) | ADT and LHRH agonist | Advanced prostate cancer and ongoing hormone suppression in later disease states |
| histrelin (Vantas) | ADT and LHRH agonist | Advanced prostate cancer |
| degarelix (Firmagon) | ADT and GnRH antagonist | Advanced prostate cancer |
| relugolix (Orgovyx) | ADT and GnRH antagonist | Advanced prostate cancer, with hormone suppression often continued if castration-resistant disease develops |
| bicalutamide (Casodex) | First-generation anti-androgen | Metastatic prostate cancer when used with an LHRH analog, but it may also be used briefly for testosterone flare protection |
| nilutamide (Nilandron) | First-generation anti-androgen | Metastatic prostate cancer when used with surgical castration |
| enzalutamide (Xtandi) | Androgen receptor pathway inhibitor | Castration-resistant, metastatic castration-sensitive, or high-risk biochemical recurrent nonmetastatic disease |
| apalutamide (Erleada) | Androgen receptor pathway inhibitor | Nonmetastatic castration-resistant or metastatic castration-sensitive disease |
| darolutamide (Nubeqa) | Androgen receptor pathway inhibitor | Nonmetastatic castration-resistant or metastatic castration-sensitive disease |
| abiraterone (Zytiga, Yonsa) | CYP17 enzyme inhibitor | Metastatic castration-resistant or metastatic high-risk castration-sensitive disease |
Chemotherapy, radiopharmaceuticals, targeted therapy, and immune therapy
These drugs are typically used in more specific advanced, metastatic, or biomarker-selected settings when they are being used for prostate cancer.
| Medication (brand) | Drug class | Public source disease setting |
|---|---|---|
| docetaxel (Taxotere) | Chemotherapy | Metastatic prostate cancer, including hormone-refractory disease by label and hormone-sensitive disease by guideline |
| cabazitaxel (Jevtana) | Chemotherapy | Metastatic castration-resistant disease after docetaxel |
| radium Ra 223 dichloride (Xofigo) | Radiopharmaceutical | Castration-resistant disease with symptomatic bone metastases and no known visceral metastases |
| lutetium Lu 177 vipivotide tetraxetan (Pluvicto) | Radioligand therapy | PSMA-positive metastatic castration-resistant disease after androgen receptor pathway inhibitor therapy where taxane chemotherapy may be delayed or after prior taxane therapy |
| olaparib (Lynparza) | PARP inhibitor | HRR-mutated metastatic castration-resistant disease after enzalutamide or abiraterone, or BRCA-mutated metastatic castration-resistant disease with abiraterone and prednisone |
| rucaparib (Rubraca) | PARP inhibitor | BRCA-mutated metastatic castration-resistant disease after androgen receptor-directed therapy |
| talazoparib (Talzenna) | PARP inhibitor | HRR gene-mutated metastatic castration-resistant disease with enzalutamide |
| niraparib and abiraterone (Akeega) | PARP inhibitor combination | BRCA-mutated metastatic castration-resistant disease with prednisone and ongoing hormone suppression |
| sipuleucel-T (Provenge) | Cellular immunotherapy | Asymptomatic or minimally symptomatic metastatic castrate-resistant or hormone-refractory disease |
Bone health and bone metastasis medicines
Brand, dose, schedule, and diagnosis matter because the same ingredient can be used for very different reasons.
| Medication (brand) | Drug class | Public source disease setting |
|---|---|---|
| denosumab (Xgeva) | Bone-targeted agent | Bone metastases from prostate cancer or another solid tumor when used in oncology dosing |
| denosumab (Prolia) | Bone-targeted agent | Osteoporosis or bone loss in men receiving ADT for nonmetastatic prostate cancer |
| zoledronic acid (Zometa) | Bone-targeted agent | Documented bone metastases from solid tumors, with prostate cancer use generally after progression on hormonal therapy |
What a medication can and cannot tell you about a diagnosis
Some medications are associated in public sources with advanced or metastatic prostate cancer, so they may suggest questions about disease setting. Examples can include Pluvicto, Xofigo, Jevtana, Provenge, prostate cancer PARP inhibitor regimens, Zytiga, Xtandi, Erleada, Nubeqa, docetaxel for prostate cancer, and oncology-dose Xgeva or Zometa when prostate cancer is confirmed.
Other medication histories can point in a different direction. A short course of ADT given with radiation may be part of treatment for localized or locally advanced cancer. Bicalutamide can sometimes be used briefly to reduce testosterone flare when hormone therapy starts. Prolia is often used for osteoporosis or ADT-related bone loss in nonmetastatic prostate cancer. Several medicines also have non-prostate uses. The medication name should be treated as a prompt for questions, not a conclusion.
Five-year relative survival by stage at diagnosis
SEER 21 excluding Illinois, prostate cancer cases diagnosed from 2016 to 2022.
| Localized | 100% |
|---|---|
| Regional | 100% |
| Distant | 40.1% |
SEER reports five-year relative survival as 100.0 percent for localized and regional prostate cancer and 40.1 percent for distant disease, based on SEER 21 excluding Illinois cases diagnosed from 2016 to 2022. These are population statistics, not a person's prognosis.
Why the timing of a diagnosis matters
Advanced-stage prostate cancer can sometimes follow a missed or delayed diagnosis. One possible reason to ask questions is a history of earlier elevated PSA results, abnormal digital rectal exam findings, urinary or bone symptoms, missed referrals, delayed biopsy, lost imaging results, or delayed communication of abnormal results.
That is not always what happened. Many advanced cancers are diagnosed promptly and progress despite good care. Some patients start advanced therapies years after an early-stage diagnosis because the cancer recurred or stopped responding to treatment. Only a medical-record review can evaluate whether there was a delay, whether earlier action could have mattered medically or legally, and whether New York time limits may affect the question.
If those timing questions sound familiar, a medication list can help organize the discussion, but it cannot answer the legal or medical question by itself.
If you or someone you love was diagnosed with advanced prostate cancer, the team at Porter Law Group can review the medical records and the timeline at no cost. There is no obligation.
Methodology and sources
This report groups medications by public U.S. Food and Drug Administration (FDA) prescribing information and by National Cancer Institute (NCI) Physician Data Query (PDQ) prostate cancer treatment summaries. FDA is the federal agency that approves drug labels, and NCI is a federal cancer research agency. The survival chart uses Surveillance, Epidemiology, and End Results Program (SEER) data, an NCI registry source, for SEER 21 excluding Illinois prostate cancer cases diagnosed from 2016 to 2022. Screening context is drawn from the American Cancer Society, NCI, and the United States Preventive Services Task Force (USPSTF), a federal prevention panel. Prostate-specific antigen (PSA) is discussed only as public screening context. New York timing information is drawn from New York Civil Practice Law and Rules (CPLR) 214-a. Medication groupings are Porter Law Group summaries of public sources, not clinical instructions, and drug descriptions should be confirmed with the treating oncology team.
